Patents by Inventor Stuart W. Bright

Stuart W. Bright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunomethods for isolating and indentifying human influx peptide transporter
    Patent number: 6270978
    Abstract: Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism.
    Type: Grant
    Filed: January 31, 1997
    Date of Patent: August 7, 2001
    Assignee: Eli lilly and Company
    Inventors: Stuart W. Bright, Anne H. Dantzig, Linda B. Tabas, J. Richard Sportsman
  • Diagnosis of colon carcinoma using monoclonal antibodies to human influx peptide transporter
    Patent number: 6001359
    Abstract: Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: December 14, 1999
    Assignee: Eli Lilly and Company
    Inventors: Stuart W. Bright, Anne H. Dantzig, Linda B. Tabas, J. Richard Sportsman
  • Monoclonal antibodies to human influx peptide transporter
    Patent number: 5824510
    Abstract: Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: October 20, 1998
    Assignee: Eli Lilly and Company
    Inventors: Stuart W. Bright, Anne H. Dantzig, Linda B. Tabas, J. Richard Sportsman
  • Monoclonal antibodies to human influx peptide transporter
    Patent number: 5500346
    Abstract: Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: March 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: Stuart W. Bright, Anne H. Dantzig, Linda B. Tabas, J. Richard Sportsman
  • Immunoassays for insulin sensitivity enhancers, insulin sensitivity enhancer antibodies, and non-thiazolidinedione insulin sensitivity enhancer compositions
    Patent number: 5466610
    Abstract: Methods have been developed to produce novel compounds by covalently coupling thiazolidinedione insulin sensitivity enhancers (ISEs) to proteins. These novel compounds are well suited for producing antibodies, which are specific for thiazolidinedione ISEs and which are well suited for fluorescent immunoassays of thiazolidinedione and non-thiazolidinedione ISEs in buffers and biological tissues. Antibodies also are well suited for high-volume screening for immunologically related novel, non-thiazolidinedione and thiazolidinedione ISEs.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: November 14, 1995
    Assignee: Eli Lilly and Company
    Inventors: Stuart W. Bright, Gerald Gold, Scott W. Sage, John R. Sportsman
  • Purified mammalian cell binding receptor for bacterial lipopolysaccharide endotoxin and monoclonal antibody
    Patent number: 5045466
    Abstract: The invention is directed to hydridoma cell lines and the monoclonal antibodies produced by the cell lines, where the monoclonal antibodies specifically bind to the lipopolysaccharide endotoxin binding receptor of mammalian cells. Specifically, the monoclonal antibodies binds to a cell receptor which has a molecular mass of 80 kilodaltons, and is specific for the lipid A component of the lipopolysaccharide endotoxin. The monoclonal antibodies are specific for a carbohydrate component of the binding receptor in one instance, and for a protein/peptide receptor in another.
    Type: Grant
    Filed: July 7, 1989
    Date of Patent: September 3, 1991
    Assignee: University of Kansas
    Inventors: David C. Morrison, Taiying Chen, Mei-Guey Lei, Stuart W. Bright, Linda M. Flebbe